Anti-AgingTarget: ThymusImmune

Thymalin

Thymic Extract · Тималин

Thymalin is the pharmaceutical thymus polypeptide extract - Cytamin-era injectable used in CIS practice. It is not Vilon, not Thymogen, not thymosin alpha-1, and not a single CAS-numbered tetrapeptide.

Not FDA-approved - research chemical
Reviewed by CalcMyPeptide Editorial Team
Last updated: September 2026Evidence: Moderate6 peer-reviewed citations
Typical research dose
10 mg/day for 10 days
Frequency
1× daily (10-day course)
Half-life
Short (peptide mixture)
Common vials
10 mg
CAS
N/A (biological peptide extract)
Molecular weight
Mixture (thymic extract)

Use-case scores

0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.

  • Longevity / aging3.5/10

    Khavinson-school tissue peptide. Single-lab concentration after haircut. Not a Western Phase 3 geroprotector.

  • Immune3.5/10

    Thymus/immune organ map in the school. Not Zadaxin and not a US immune-deficiency drug.

Compound card

Sequence
Thymus extract / historic clinic SKU
Class
Khavinson pharmaceutical extract (Thymus)
Formula
Mixture of thymic peptides (<10 kDa)
Status
Not FDA-approved · research use
Dose it
10 mg + 2 mL BAC water → 5 mg/mL · 10000 mcg ≈ 200 units (U-100)
Open in calculator

How it works

Thymalin is a thymic bioregulator peptide developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It consists of a standardized extract from the thymus gland containing small regulatory peptides (molecular weight <10 kDa).

Thymalin restores thymic function in aging immune systems by promoting T-cell differentiation, maturation, and activation. The thymus involutes significantly after puberty - by age 60, most thymic tissue has been replaced by fat. Thymalin works by restoring thymic peptide signaling, rebooting T-cell production. A Khavinson-group elderly follow-up of thymic extract plus epithalamin/epitalon is the paper people mean when they say 12-year mortality. That is a concentrated Russian series, not a US mortality indication, and it is not a license to treat immunodeficiency from this page.

Source: PMID: 15677927

Khavinson map

Canonical 41
Class
Pharmaceutical extract (Cytamin-era)
Organ
Thymus
Target
Thymus
System
Immune
Sequence
Mixture / not a single CAS
Тималин

Used in bioregulator stacks

Manufacturer-style organ combinations - not FDA protocols. Every name is a live leaf.

The Khavinson school

Vladimir Khatskelevich Khavinson (1946–2024) spent five decades at what became the St. Petersburg Institute of Bioregulation and Gerontology arguing a simple, stubborn idea: aging is, in part, a failure of tissue-specific peptide signals, and those signals can be restored. The first products were not “peptides” in the Instagram sense. They were Cytamins - polypeptide fractions isolated from a named organ of young animals. Later commercial refinements of those fractions are sold as Cytomaxes (Cytomed / NPCRIZ): still mixtures, still oral capsules, still defined by the source organ rather than a single sequence. When the group identified short active motifs inside those mixtures, they synthesized them as Cytogens - di-, tri-, and tetrapeptides with a one-letter code (KE, AEDG, KED, EDR, KEDP, and so on).

That three-layer stack is the whole map. Cytamin / pharmaceutical extracts (Thymalin, Epithalamin, Cortexin, Retinalamin, Prostatilen) are the clinic-era injectables registered in the former Soviet pharmacopeia. Cytomaxes are the capsule complexes Cytomed still lists as a 21-SKU organ line. Cytogens are the defined synthetics. English-language educators, including Brenden Henry’s public writing at Peptide Science Institute, add a further commercial distinction - later analog SKUs (N-acetyl, amidate, “V2” complexes) sold as more stable or more diverse than the original Cytomed lots. That last layer is a product taxonomy, not a Khavinson paper. We describe it so readers are not gaslit by three bottles with the same organ name. We do not reproduce paid Peptide Mastery protocols, Precision Cell Method language, or anyone else’s course IP.

Full Cytamin → Cytomax → Cytogen map, literature limits, and how we counted 41

The mechanism Khavinson published is epigenetic, not receptor-agonist in the GLP-1 sense. Short peptides are claimed to enter nuclei, interact with DNA/histones, and reopen tissue-specific transcription that condensed with age (heterochromatin → euchromatin). Reviews in the Bulletin of Experimental Biology and Medicine and Neuroendocrinology Letters (PMID 14523363, 15677927, 23888677) are the citable core. Complementary GI pharmacology is not mystical: di- and tripeptides are PEPT1/LAT substrates, which is why oral capsules are even a conversation. What is not established in Western Phase 3 programs is organ-by-organ disease treatment, telomere reversal as a clinical endpoint, or the manufacturer claim that Cytomax is “a third stronger” than Cytogen. Those are NPCRIZ marketing sentences.

Khavinson’s group published hundreds of papers, many in Russian, many in the same journal family. That is a real literature. It is also a literature with limited independent Western replication, small n, and a habit of using one review PMID as a stamp on every organ. On this site a leaf earns its organ story, its Cytomax↔Cytogen pair, its sequence if it has one, and an honest sentence about what has not been shown. Reconstitution math belongs on cytogens sold as vials. Cytomax capsules do not get a fake 5 mg vial.

The 41 we treat as canonical are the 21 Cytomaxes on the public e-peptide/Cytomed list, the 12 Cytogens on that same commercial line (including Vesilut, which Western catalogs often drop), plus eight historically load-bearing molecules that sit beside the capsule SKUs: Epitalon, Vilon, Thymogen, Livagen, Cortagen, Prostamax, Thymalin, and Epithalamin. Honluten, Cortexin, Retinalamin, Prostatilen, Thymulin, N-acetyl-epitalon-amidate, Pinalex, and the GPL Man / GPL Femme kits are covered as adjacent - same school or same storefront, not padded into a fake 41.

Public English-language teaching (including Brenden Henry at peptidescienceinstitute.com) is cited as context, not copied. Paid Peptide Mastery / Peptide Salvation text stays theirs.

History of this molecule

This is the immune extract that actually behaved like a hospital product: ampoules, courses, geriatric and infectious-disease use in Russian-language literature. Vladonix is the later oral Cytomax complex from the same organ. The cytogens are the defined motifs.

English blogs credit Thymalin+Epitalon combinations with mortality reduction in elderly cohorts. Read the papers for which preparation, which dose, which control. Do not sell that as a US indication.

TA-1 (Zadaxin) is a 28-mer with a separate development path. TB-500 is a thymosin-β4 fragment. Neither is Thymalin.

Caveats

Mixture product: lot fingerprint, animal source, no single sequence. Autoimmune caution. Not TA-1.

Full 41-map: Khavinson bioregulators index · Bioregulator stacks

Goal context

Thymic extract, not Tα1

Thymalin is the extract-era product in the Thymus line, not a Cytomax capsule and not thymosin alpha-1. Russian clinic history is real. A 50% mortality slogan is not a US label.

Often paired with Epitalon in school folklore

Different organs and different materials: thymic extract vs pineal tetrapeptide. School combination follow-ups exist. That is not an FDA mortality claim.

Research Use Cases

  • ✓Thymic extract identity vs Vilon vs Vladonix vs thymosin alpha-1
  • ✓Not a post-cancer immune restoration or infection protocol
  • ✓Not a US mortality-reduction drug

Dosing

PhaseDoseFrequencyNotes
Khavinson Protocol10 mgDaily IM or SC for 10 consecutive daysStandard Khavinson immune reconstitution protocol. Repeat 1-2 times per year. Often paired with Epitalon cycles.

Administration

Route / form
Pharmaceutical extract - historically intramuscular courses. Not a Cytomax capsule and not a sublingual tablet.
Timing
Course-based injectable / extract timing per the pharmaceutical presentation - food does not change an IM or parabulbar shot.
Empty stomach?
No - These are clinic-era injectables or suppositories, not capsules. Food timing does not apply.

Thymalin: CIS IM extract vs Not Vladonix / not KE

CIS IM extract
Bioavailability
CIS pharmaceutical thymus polypeptide extract. Historical route is intramuscular courses, not a KE research-chem SubQ lifestyle peptide.
Dose note
Ampoule / clinic kit: mix per the pharmaceutical presentation. Do not invent a 5 mg/mL BAC SubQ lifestyle chart for an extract lot. Russian labeling folklore is on the order of 10 mg/day for ~10 days. US vials printed “Thymalin” may be extract, KE, or unknown. Ask what is in the vial before doing any math.
Advantages
  • Clinic-era registered presentation in CIS practice. Real hospital object, not a blog tetrapeptide.
  • Mixture by design (Cytamin-era). That is the point of the extract layer.
  • Food does not change an IM shot.
Considerations
  • Not Vilon (KE), not Thymogen (EW), not Crystagen (EDP), not Thymulin (FTS), not TA-1 (Zadaxin), not TB-500.
  • Lot fingerprint, animal source, no single CAS. Autoimmune caution.
  • Do not paste a 5 mg BAC chart from a cytogen vial onto this ampoule.
Not Vladonix / not KE
Bioavailability
Thymalin is not a swallowed Cytomax. The oral thymus cousin is Vladonix (capsule complex). Swallowing Vladonix is not a Thymalin course. KE capsules are Vilon.
Dose note
If the bottle is oral capsules, you bought Vladonix or a cytogen, not this extract. There is no honest Thymalin capsule dose sheet on this leaf.
Advantages
  • The map has an oral thymus product (Vladonix). Use that leaf for capsules.
  • Keeps extract identity from collapsing into KE milligrams.
  • Not a sublingual tablet. Nobody manufactures this SKU that way.
Considerations
  • English catalogs flatten Thymalin / Vilon / Vladonix into one “thymus peptide.”
  • Combination longevity follow-ups that blogs call “Thymalin+Epitalon” must be read for which preparation was injected.
  • Not a sublingual immune melt.
Recommendation: Thymalin is a pharmaceutical extract: historically IM ampoule courses in CIS practice. It is not Vilon, not Thymogen, not Crystagen, not Vladonix, not Thymulin, and not a 5 mg BAC SubQ chart. If you want oral thymus, that is Vladonix. If you want KE, that is Vilon.

Timeline

Day 5-10 (course)
T-cell activation markers improve. Immune resilience begins to restore.
Month 1-3 post-course
Sustained immune reconstitution. Fewer infections reported in school literature — not a US vaccine-response label.

Who it is for

Immune Reconstitution / Thymic Support

Moderate

Thymic extract in the Khavinson school. Not thymosin alpha-1. Mortality slogans are not a label.

Longevity / Anti-Aging

Moderate

School combination follow-up, not an FDA mortality claim.

Reconstitution

Vial
10 mg
Diluent
2 mL
Concentration
5 mg/mL
Per Unit (100u syringe)
50 mcg
Dose of 10000 mcg = 200 units on a 100-unit insulin syringe

Safety & Considerations

Used in Russian and CIS clinic programs for decades. That history is not a US safety NDA. IM or SubQ. "No significant adverse events" is that literature, not a Western Phase 3 file.

Regulatory & Legal Status

FDA Status (US)
Research Only

Approved in Russia as Tactivin®; not FDA-approved

WADA Status (2026)
Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Limits of current evidence

  • Extract ≠ synthetic cytogen ≠ Cytomax capsule.
  • Longitudinal Khavinson combination data is not an FDA mortality claim.
  • This site will not treat the named organ disease from a peptide page.

Human evidence

Moderate · Khavinson-school extract (not a US NDA)

  • Extract ≠ synthetic cytogen ≠ Cytomax capsule.
  • Longitudinal Khavinson combination data is not an FDA mortality claim.

Verdict

Thymalin is the extract-era product in the Thymus line, not a Cytomax capsule and not a one-letter cytogen. Russian clinic history is real. A 50% mortality slogan is not a US label.

Interactions & Contraindications

Immunosuppressants and transplant belong with a prescriber. Annual 10-day cycles are the school’s language, not an FDA duration.

Synergies & Common Stacks

School combination follow-ups exist. They are not a 12-year 50% mortality NDA on this extract.

Extract vs defined 28-mer. Same organ story, different material.

Frequently Asked Questions

Thymalin vs Vladonix vs Vilon vs TA-1?▼
Thymalin = pharma thymus extract. Vladonix = thymus Cytomax. Vilon = KE. TA-1 = 28-mer (Zadaxin), different drug.
Single sequence?▼
No. Extract. That is the point of Cytamins.
15-year longevity study?▼
Khavinson-group combination follow-ups exist. Read which extract/synthetic was used. Not an FDA label.
Reconstitution?▼
Ampoule/vial extract products are mixed per the pharmaceutical presentation. Do not invent a 5 mg/mL BAC SubQ lifestyle chart. Research-chem “Thymalin 10 mg” should be treated as identity-unknown until proven. Oral thymus is Vladonix; KE is Vilon.
How does Thymalin relate to Epitalon?▼
Different organs and different materials: thymic extract vs pineal tetrapeptide. School combination follow-ups exist. A 50% mortality slogan is not a US label on this SKU.
What is the Thymalin protocol?▼
10 mg daily via intramuscular or subcutaneous injection for 10 consecutive days. Repeat 1-2 times per year. This cycled approach mirrors the Khavinson research protocols.

References

  1. Khavinson VKh, Morozov VG “Peptide regulation of aging: from experimental studies to clinical practice.” Advances in Gerontology (2003). PMID: 14523363
  2. Khavinson VKh, Anisimov VN “Peptide bioregulators: a new class of geroprotectors. Message 1: results of experimental studies.” Bulletin of Experimental Biology and Medicine (2000). PMID: 11182816
  3. Khavinson VKh et al. “Tissue-specific effects of peptides.” Bulletin of Experimental Biology and Medicine (2005). PMID: 15677927
  4. Khavinson VKh, Lin’kova NS, Tarnovskaya SI “Short peptides regulate gene expression.” Bulletin of Experimental Biology and Medicine (2013). PMID: 23888677
  5. Khavinson VK, et al. “Thymic peptides in the treatment of cancer.” Int J Immunopharmacol (2000). PMID: 11137612
  6. Khavinson VK, Morozov VG. “Peptide bioregulators: a new class of geroprotectors.” Bull Exp Biol Med (2000). PMID: 10977940

📚 Related Articles

Looking for a trusted source? See our recommended suppliers

Independently tested · COA-verified · Save 10% with our exclusive code

See suppliers →